Company profile: Imunon
1.1 - Company Overview
Company description
- Provider of nucleic acid-based immunotherapy and vaccine platforms that harness the body's immune system, including TheraPlas, a nonviral delivery system for anti-cancer nucleic acid therapies initially targeting advanced ovarian cancer; PlaCCine, a multivalent nucleic acid vaccine platform for infectious diseases and cancer; FixPlas, for universal cancer vaccines; and IndiPlas, for personalized neoepitope cancer vaccines.
Products and services
- IndiPlas: Develops a personalized platform for cancer vaccines, with pre-clinical work underway for a neoepitope cancer vaccine
- PlaCCine: Architects a platform for developing nucleic acid vaccines for infectious diseases and cancer, leveraging a multivalent approach to elicit a robust immune response
- TheraPlas: Engineers a nonviral delivery system for immunotherapies and anti-cancer nucleic acid-based therapies, initially targeting advanced ovarian cancer
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Imunon
AvenCell Therapeutics
HQ: United States
Website
- Description: Provider of switchable and allogeneic CAR-T cell therapy platforms, including a Universal Switchable CAR with soluble targeting modules for hematologic malignancies and solid tumors; a CRISPR/Cas9-based platform enabling off-the-shelf CAR-T that overcomes graft-versus-host disease and immune rejection; and therapies AVC-101 (CD123 autologous) and AVC-201 (allogeneic UniCAR) for relapsed/refractory AML.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AvenCell Therapeutics company profile →
Formula Pharmaceuticals
HQ: United States
Website
- Description: Provider of oncology-focused CAR immunotherapies leveraging an allogeneic source, non-viral transfection, and a differentiated immune effector cell, plus diagnostic tests and research reagents including camelid nanobodies, a canine heartworm/tick-borne disease test, a SARS-CoV-2 antigen test, phosphate assay kits, leukocyte isolation solutions, and SDS-PAGE buffers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Formula Pharmaceuticals company profile →
Vortex Biosciences
HQ: United States
Website
- Description: Provider of oncology diagnostics integrating cancer biology, microfluidic engineering, and informatics to isolate and characterize circulating tumor cells (CTCs). Offers the VTX-1 Liquid Biopsy System for label-free isolation of viable CTCs from blood, CTC enrichment using disposable cartridges, CTC analysis and downstream assays, and cell handling in formats compatible with different workflows.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vortex Biosciences company profile →
BioNovion
HQ: United States
Website
- Description: Provider of immune oncology antibody discovery and development focused on antibodies for the immune therapy of cancer; U.S.-based, founded in 2011 and acquired by Aduro BioTech in 2015.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioNovion company profile →
Auron Therapeutics
HQ: United States
Website
- Description: Provider of cancer therapeutics focused on transforming malignant cells toward more normal function. Offerings include AURIGIN, an AI/ML platform to identify and target drivers of tumor cell plasticity and altered cellular states in cancer, and AUTX-703, an orally available small molecule therapy targeting KAT2A/B for small cell lung cancer, neuroendocrine prostate cancer, and acute myeloid leukemia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Auron Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Imunon
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Imunon
2.2 - Growth funds investing in similar companies to Imunon
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Imunon
4.2 - Public trading comparable groups for Imunon
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →